Sharemaestro Newsreel

DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history

This article provides a comprehensive overview of DiaMedica Therapeutics Inc. (DMAC), including its current stock price, financial statistics, historical data, and analyst insights. It highlights DMAC as a clinical-stage biopharmaceutical company focused on ischemic diseases, with its lead candidate DM199 in Phase 2/3 trials. …

AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031

This article provides price predictions for AbCellera Biologics Inc. • Robinhood Token (ABCL) from 2026 to 2045, based on Bybit AI's analysis of user-driven Consensus Ratings and historical patterns. It forecasts a positive trend for ABCL's price, with significant potential ROI over the years, …

Karyopharm Therapeutics has cash to last only into next month

Newton-based biotech Karyopharm Therapeutics is facing a severe cash crisis, with its funding expected to run out within weeks. The company also has a significant debt payment due in September, putting it at risk of default without new financing. Richard Paulson is the CEO …

KZIA Initiates Coverage On by Canaccord Genuity -- Price Target Announced at $29

Canaccord Genuity has initiated coverage on Kazia Therapeutics (KZIA) with a 'Buy' rating and a price target of $29.00, significantly higher than its current market price of $13.09. Despite this positive analyst outlook and strong momentum, the company holds a low GF Score™ of …

XBiotech: Q2 Earnings Snapshot

This article is an earnings snapshot for XBiotech's Q2 performance. It is a placeholder without actual financial details, suggesting that the full earnings report would contain the relevant financial data.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wall Street analysts are showing bullish sentiment towards two healthcare stocks: Orchestra BioMed Holdings (OBIO) and Adagene (ADAG). H.C. Wainwright reiterated a Buy rating for Orchestra BioMed with a $10.00 price target, while LifeSci Capital maintained a Buy rating for Adagene with an $8.00 …

Wedbush Adjusts Price Target on Alto Neuroscience to $26 From $24, Keeps Neutral Rating

Wedbush has increased its price target for Alto Neuroscience from $24 to $26, while maintaining a Neutral rating on the stock. The article also briefly mentions Unity Software's fourth-quarter financial results, including a 35% year-over-year revenue increase to $609 million and a quarterly loss …

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) reported a Q2 loss of $1.04 per share, matching Zacks Consensus Estimate, but surpassed revenue estimates significantly with $3.78 million, beating expectations by 142.37%. The company's stock has performed well year-to-date, rising 58.3% against the S&P 500's 13.2% gain, …

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, leading to …

Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates

Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) Stock Price, News & Analysis

Genelux (NASDAQ:GNLX) Issues Earnings Results

MiNK outlines 4-8 patients per site per month as U.S. ARDS enrollment starts in September

Earnings Call Insights: MiNK Therapeutics (INKT) Q2 2026 MANAGEMENT VIEW * "The second quarter was an important period of execution for MiNK. We moved agenT-797 into a randomized phase two study in patients with acute lung injury and ARDS." (Co-Founder, President, CEO & Director …

Can Asceniv Help ADMA Stock Combat IG Market Challenges?

ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at risk of certain infectious diseases. The company currently markets three FDA-approved plasma-derived biologics: Asceniv (immune globulin intravenous – slra 10% liquid) …

VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18

Wedbush has increased its target price for VOR Biopharma Inc. from $18 to $27. This adjustment reflects a more optimistic outlook on the company's financial prospects by the analyst firm. The article is a brief news update published on Webull.

Capricor Therapeutics Lawsuit Focuses on Deramiocel Disclosures After CAPR Stock Drops

Capricor Therapeutics is facing a federal securities lawsuit alleging that the company failed to disclose crucial information regarding changes in the statistical analysis plan for Deramiocel, its lead therapy candidate. The lawsuit claims that these omissions, particularly concerning FDA interactions and data analysis, led …

Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Beats Estimates By $0.03 EPS

Cabaletta Bio (NASDAQ:CABA) reported a quarterly loss of $0.34 per share, exceeding analyst estimates by $0.03. Despite beating estimates, the stock fell to $2.73 during midday trading, significantly below its 52-week high of $4.23. Analysts maintain a "Moderate Buy" rating with an average price …

Maplight Therapeutics (NASDAQ:MPLT) Trading Up 6.4% - Here's Why

Maplight Therapeutics (NASDAQ:MPLT) saw its stock rise by 6.4% in midday trading on Thursday, despite significantly lower trading volume. The company holds a "Moderate Buy" consensus from analysts with an average price target of $31.17, although it recently reported an earnings per share miss. …

Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High - Here's What Happened

Candel Therapeutics (NASDAQ:CADL) recently reached a new 52-week high of $11.45, closing at approximately $11.18 on significant trading volume. Despite missing quarterly EPS expectations by $0.30 with a loss of $0.52 per share, analyst sentiment remains generally positive, holding a "Moderate Buy" consensus and …

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

Analysts have provided insights on two healthcare companies: Neurogene (NGNE) and Cardiff Oncology (CRDF). Neurogene received a "Strong Buy" consensus with a significant upside, while Cardiff Oncology received a "Moderate Buy" consensus despite a recent downgrade to "Hold" by one analyst.

Genelux (GNLX) deepens losses while funding Phase 3 cancer trial and warning on cash runway

Genelux (GNLX), a clinical-stage oncology biotech company, reported a widening net loss of $9.5 million for Q2 2026 and $18.4 million for the first half of 2026, primarily due to increased R&D expenses for its Phase 3 Olvi-Vec cancer trial. Despite a recent $18.5 …

GENELUX Corp 6M 2026: Revenue $0 Net loss $(18.4M), EPS $(0.41) — 10-Q Summary

GENELUX Corp reported its financial results for the six months ended June 30, 2026, showing no revenue, a net loss of $(18.4M), and diluted EPS of $(0.41). The company's net loss worsened compared to the prior year, primarily due to increased clinical and regulatory …

S&P 500 tags an all-time high and these 20 names have helped fuel the rally

[S&P Market Index Concept with Financial Graphs] AlexSecret The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) climbed to a fresh all-time high of 7,816.70 on Thursday, surpassing its prior record of 7,793.68 set on August 5. The benchmark advanced 0.6% for the session and is now up …

Cellectar Biosciences Releases Q2 2026 Financial Results

Cellectar Biosciences (CLRB) reported a wider-than-expected diluted loss of $0.57 per share for Q2 2026, missing analyst estimates. Despite this, the net loss of $6.9M represents an 83.2% improvement year-over-year. The clinical-stage biopharmaceutical company maintains strong analyst support for its oncology pipeline.

Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ)

Monopar Therapeutics Inc. (MNPR) was downgraded to Neutral from Overweight by Cantor Fitzgerald after a significant rally in its stock price. Cantor Fitzgerald believes the clinical-stage biopharma is now fairly valued following a nearly 90% increase over the past six months. This downgrade led …

Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY

Robbins LLP is urging investors who suffered losses in ARS Pharmaceuticals Inc. (NASDAQ: SPRY) between March 9, 2026, and June 24, 2026, to contact the firm regarding a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements about the timeline …

Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares

Laurence W. Lytton has reported a beneficial ownership of 5,592,972 shares of Codexis, Inc. (CDXS) common stock, which represents a 5.2% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing with the SEC, indicating an increase in his holdings above …

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics (ALLO) reported a narrower-than-expected Q2 2026 loss of 13 cents per share, beating the Zacks Consensus Estimate of 16 cents, primarily due to lower research and development costs. The company's cash position extended its runway into 2029, and it is progressing with …

Ascendis Pharma Slides as Investors Weigh Strong Q2 Growth Against One-Time Profit Boost

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside

Ocugen Inc. stock falls Thursday, underperforms market

Ocugen Inc. (OCGN) stock experienced a 3.57% decline on Thursday, closing at $1.35. This fall occurred despite a positive trading session for the broader market, with both the S&P 500 and Dow Jones Industrial Average seeing gains. The decrease in Ocugen's stock price broke …

Novavax Inc. stock outperforms competitors on strong trading day

Novavax Inc. (NVAX) shares rose 2.26% to $8.14, outperforming major indices like the NASDAQ Composite and Dow Jones Industrial Average. This marked the third consecutive day of gains for the stock. The positive performance occurred during a favorable trading session for the broader market.

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise by 3.28% to $10.08, marking its third consecutive day of gains. This performance occurred on a strong trading day where the NASDAQ Composite Index increased by 0.81% and the Dow Jones Industrial Average rose by …

Curis prices $5.6 million public offering at $1.50 per share By Investing.com

Curis Inc. (NASDAQ:CRIS) has priced a public offering of 3,733,334 shares of common stock and warrants at $1.50 per share, aiming to raise approximately $5.6 million. The offering includes warrants exercisable at $1.75 per share, expiring in five years, and pre-funded warrants for some …

Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next

Mirum Pharmaceuticals (MIRM) saw its stock drop 6.4% despite raising its 2026 net product sales guidance, due to reporting significantly wider net losses in the second quarter of 2026. The company highlighted progress with breakthrough therapy designation for volixibat and potential launch timing for …

Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management

Janus Henderson Group Ltd., through its asset management subsidiaries, reported beneficial ownership of 5,909,184 shares of Mirum Pharmaceuticals, Inc. common stock, representing 9.7% of the class as of June 30, 2026. These shares are managed in client accounts (Managed Portfolios) where Janus Henderson holds …